Dibya Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dibya Das has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Himangshu Sekhar Maji
Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata
2 shared publications - Pintu Kumar DE
Department of Pharmaceutical Technology, JIS University, Kolkata, India
2 shared publications - Abhishek Ghosh
Postgraduate Institute of Medical Education and Research, Chandigarh, India
1 shared publication - Abhishek Mukherjee
Section on Neural Developmental Dynamics, Division of Developmental Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development
1 shared publication Anirbandeep Bose
1 shared publication- Anirbandeep Bose
Adamas University
1 shared publication
Latest Publications
- Open Access
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 2940
Phytochemical Screening and Evaluation of the Antioxidant, Antimicrobial and Antihyperlipidemic Activities of the Hydroalcoholic Extract from the Peel of Musa paradisiaca
Dyslipidemia is associated with an increased risk of atherosclerotic cardiovascular disease, while conventional lipid-lowering drugs may be inadequate or poorly tolerated. Banana (Musa paradisiaca) peel, an abundant agri-food waste rich in antioxidant phytochemicals, represents a sustainable and low-cost candidate for managing lipid disorders. Previous studies in other parts of the world highlighted the antidiabetic and hypolipidemic potential of kepok banana peel extract. Therefore, the present study aimed to investigate the antioxidant, antimicrobial, and antihyperlipidemic activities of hydroalcoholic extract prepared from banana peels (BPE) collected from West Bengal, India. Phytochemical screening was performed, and antioxidant capacity was evaluated using in vitro DPPH and reducing power assays. Antibacterial activity against E. coli was assessed by agar well diffusion. In vivo antihyperlipidemic efficacy was screened in rats subjected to a high-fat diet and treated with BPE (200 or 400 mg/Kg), Atorvastatin (10 mg/Kg) for 28 days prior to biochemical assessment, and compared with the untreated control group. Phytochemical screening suggested the presence of several biologically active phytoconstituents, such as saponins, phytosterols, flavonoids, carbohydrates, glycosides, alkaloids, phenols, and terpenoids. BPE scavenged DPPH radicals with an IC₅₀ of 88.11 ± 6.23 µg/mL and showed concentration-dependent reducing power. The prominent zone of inhibition (2.45cm at 1000µg/mL) against E. coli confirmed its antimicrobial properties. In hyperlipidemic rats, BPE significantly limited weight gain and normalized cholesterol, triglycerides, and LDL, while restoring HDL (p<0.01). Overall, BPE demonstrated strong antioxidant, antibacterial, and lipid-lowering effects, supporting its potential as a cost-effective, eco-friendly nutraceutical for managing oxidative stress and dyslipidemia, warranting further clinical investigation.
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 2940
Open AccessPhytochemical Screening and Evaluation of the Antioxidant, Antimicrobial and Antihyperlipidemic Activities of the Hydroalcoholic Extract from the Peel of Musa paradisiaca
Dyslipidemia is associated with an increased risk of atherosclerotic cardiovascular disease, while conventional lipid-lowering drugs may be inadequate or poorly tolerated. Banana (Musa paradisiaca) peel, an abundant agri-food waste rich in antioxidant phytochemicals, represents a sustainable and low-cost candidate for managing lipid disorders. Previous studies in other parts of the world highlighted the antidiabetic and hypolipidemic potential of kepok banana peel extract. Therefore, the present study aimed to investigate the antioxidant, antimicrobial, and antihyperlipidemic activities of hydroalcoholic extract prepared from banana peels (BPE) collected from West Bengal, India. Phytochemical screening was performed, and antioxidant capacity was evaluated using in vitro DPPH and reducing power assays. Antibacterial activity against E. coli was assessed by agar well diffusion. In vivo antihyperlipidemic efficacy was screened in rats subjected to a high-fat diet and treated with BPE (200 or 400 mg/Kg), Atorvastatin (10 mg/Kg) for 28 days prior to biochemical assessment, and compared with the untreated control group. Phytochemical screening suggested the presence of several biologically active phytoconstituents, such as saponins, phytosterols, flavonoids, carbohydrates, glycosides, alkaloids, phenols, and terpenoids. BPE scavenged DPPH radicals with an IC₅₀ of 88.11 ± 6.23 µg/mL and showed concentration-dependent reducing power. The prominent zone of inhibition (2.45cm at 1000µg/mL) against E. coli confirmed its antimicrobial properties. In hyperlipidemic rats, BPE significantly limited weight gain and normalized cholesterol, triglycerides, and LDL, while restoring HDL (p<0.01). Overall, BPE demonstrated strong antioxidant, antibacterial, and lipid-lowering effects, supporting its potential as a cost-effective, eco-friendly nutraceutical for managing oxidative stress and dyslipidemia, warranting further clinical investigation.
- 30 September 2023
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 16 (9) , 4229-4233
Assessment of Subchronic Dermal Toxicity of Ziziphus oenoplia extract incorporated Carbopol hydrogel on New Zealand White Rabbits
Since the ancient times herbal formulations have been used in the ailment of various diseases. The plant Ziziphus oenoplia is also known for its various pharmacological activities including wound healing property. But evaluation of the safety of the herbal formulations after application is necessary for their acceptance in the scientific community. As a result, in the current research work sub-chronic dermal toxicity of Ziziphus oenoplia extract incorporated herbal hydrogel was conducted to evaluate its safety profile upon application on the skin. Three different doses of extract loaded hydrogel (1g/kg, 2g/kg and 4g/kg body weight of animals), blank (4g/kg body weight) and control (0.9% NaCl solution) was applied on 15 adult healthy New Zealand White Rabbits in groups of 3 animals each. Application was done on the dorso-ventricular trunk of the rabbits and the animals were observed for 28 days for any clinical signs of intoxication, food consumption and change in body weight gain. After completion of the experiment no skin irritation such as erythema, edema or eschar formation was observed in all the animal groups. No signs of mortality or morbidity was seen. Food consumption was found to be normal and no drastic increase in body weight gain of the rabbits was observed in the control, blank and test groups of rabbits. From this study it was concluded that the Ziziphus oenoplia extract loaded Carbopol hydrogel was non-toxic and could be safely used as a dermal formulation.
- 30 September 2023
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 16 (9) , 4229-4233
Assessment of Subchronic Dermal Toxicity of Ziziphus oenoplia extract incorporated Carbopol hydrogel on New Zealand White Rabbits
Since the ancient times herbal formulations have been used in the ailment of various diseases. The plant Ziziphus oenoplia is also known for its various pharmacological activities including wound healing property. But evaluation of the safety of the herbal formulations after application is necessary for their acceptance in the scientific community. As a result, in the current research work sub-chronic dermal toxicity of Ziziphus oenoplia extract incorporated herbal hydrogel was conducted to evaluate its safety profile upon application on the skin. Three different doses of extract loaded hydrogel (1g/kg, 2g/kg and 4g/kg body weight of animals), blank (4g/kg body weight) and control (0.9% NaCl solution) was applied on 15 adult healthy New Zealand White Rabbits in groups of 3 animals each. Application was done on the dorso-ventricular trunk of the rabbits and the animals were observed for 28 days for any clinical signs of intoxication, food consumption and change in body weight gain. After completion of the experiment no skin irritation such as erythema, edema or eschar formation was observed in all the animal groups. No signs of mortality or morbidity was seen. Food consumption was found to be normal and no drastic increase in body weight gain of the rabbits was observed in the control, blank and test groups of rabbits. From this study it was concluded that the Ziziphus oenoplia extract loaded Carbopol hydrogel was non-toxic and could be safely used as a dermal formulation.
- Open Access
- 7 March 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 219-227
A STRATEGIC PROCESS DEVELOPMENT AND IN VITRO CYTOTOXICITY ANALYSIS OF PACLITAXEL-LOADED LIPOSOMES
Objective: Liposomes are the controlled-release dosage form that improves the therapeutic efficacy of the drugs, prolongs the duration of action, reduces dosage frequency, and improves patient compliance. Methods: The thin-film hydration method was used to prepare Paclitaxel liposomes. In this process, cholesterol and sodium deoxycholate were used for the formulation, while chloroform and methanol were used as diluents. Percentage (%) drug release study was carried out in phosphate buffer at pH 7.4 in USP apparatus II (Paddle type)Model no VDA-8D, Veego, Mumbai, India. Results: Paclitaxel liposomes of various batches showed a percentage yield ranging from 38 to 84%. It was observed that (Encapsulation efficiency)EE% of Batches B1 to B10 were 0,62.33,59.51,50.21,44.30,82.25,88.95,72.34,77.37 and 70.63 percentage, respectively. Data fitting to the Peppas, Higuchi, 1st-order, and zero-order models was used to examine the optimized liposome (B7) release kinetic mechanism. Data comparison was done using the correlation coefficient (R2). Zero-order had an observed correlation coefficient (R2) of 0.9988, which was greater than that for other models. Therefore, it was clear that the medication was released from the formulation after the zero-order release. Conclusion: The prepared liposomes were subjected to various evaluation parameters like SEM, zeta potential, particle size analysis, drug release study, etc. Data showed that an increased concentration of cholesterol increases the drug release from liposomes. Microscopic images of the B7 batch revealed that liposomes are spherical and have regular surfaces. Formulation B7 shows good results and can be considered an optimized batch that has been selected for further cell line studies. The statistical analysis was used to support the improved formulation.
- 7 March 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 219-227
Open AccessA STRATEGIC PROCESS DEVELOPMENT AND IN VITRO CYTOTOXICITY ANALYSIS OF PACLITAXEL-LOADED LIPOSOMES
Objective: Liposomes are the controlled-release dosage form that improves the therapeutic efficacy of the drugs, prolongs the duration of action, reduces dosage frequency, and improves patient compliance. Methods: The thin-film hydration method was used to prepare Paclitaxel liposomes. In this process, cholesterol and sodium deoxycholate were used for the formulation, while chloroform and methanol were used as diluents. Percentage (%) drug release study was carried out in phosphate buffer at pH 7.4 in USP apparatus II (Paddle type)Model no VDA-8D, Veego, Mumbai, India. Results: Paclitaxel liposomes of various batches showed a percentage yield ranging from 38 to 84%. It was observed that (Encapsulation efficiency)EE% of Batches B1 to B10 were 0,62.33,59.51,50.21,44.30,82.25,88.95,72.34,77.37 and 70.63 percentage, respectively. Data fitting to the Peppas, Higuchi, 1st-order, and zero-order models was used to examine the optimized liposome (B7) release kinetic mechanism. Data comparison was done using the correlation coefficient (R2). Zero-order had an observed correlation coefficient (R2) of 0.9988, which was greater than that for other models. Therefore, it was clear that the medication was released from the formulation after the zero-order release. Conclusion: The prepared liposomes were subjected to various evaluation parameters like SEM, zeta potential, particle size analysis, drug release study, etc. Data showed that an increased concentration of cholesterol increases the drug release from liposomes. Microscopic images of the B7 batch revealed that liposomes are spherical and have regular surfaces. Formulation B7 shows good results and can be considered an optimized batch that has been selected for further cell line studies. The statistical analysis was used to support the improved formulation.
- Open Access
- 7 November 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 42-50
DETERMINATION OF METFORMIN AND SITAGLIPTIN IN HEALTHY HUMAN VOLUNTEERS' BLOOD PLASMA AND ITS BIOEQUIVALENCE STUDY UNDER FASTING CONDITION
Objective: Metformin hydrochloride and sitagliptin are the oral anti-hyperglycemic medications used to treat type 2 diabetes and are used in combination to treat patients. In this work, we have developed a bioanalytical method for simultaneous estimation of both the drugs form some formulation and subsequently the validation of the developed method metformin and sitagliptin in human plasma. Methods: The stability studies were done as per USFDA and EMA guidelines. The sample extraction approach presented here was a straightforward liquid extraction. The linearity range of metformin was 11.72 ng/ml to 3000 ng/ml, and sitagliptin was 4.68 ng/ml. to 1200 ng/ml. For metformin, the LOD was 1.0 ng/ml, and LLOQ was 11.72 ng/ml. and for sitagliptin, the LOD was 0.75 ng/ml, and LLOQ was 4.68 ng/ml. LC-ESI-MS/MS was used to develop and validate this method using the Phenomenex Kinetex C18 column. Milli-Q water containing 10 mmol Ammonium Acetate (pH =3.6) and Acetonitrile containing 0.1% Formic Acid (pH =2.4) as solvent systems for the estimation of Sitagliptin in a single dose. Metoprolol is used as an Internal Standard. Results: The total chromatographic run time was only 7.0 min, and the elute time of metformin and sitagliptin was 3.94 min and 3.97 min, respectively. Relative Bioavailability was found at 101.14% for Metformin and 96.96% for Sitagliptin. The overall results show that the Cmax, AUC0-t, and AUC0-∞ for metformin and sitagliptin were within the acceptable limit of 80%-125%. Conclusion: This bioanalytical method was successfully applied in the bioequivalence study. The study design was a randomized, open-label, two treatment, two-period, two sequences, single-dose, crossover bioequivalence study under fasting conditions.
- 7 November 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 42-50
Open AccessDETERMINATION OF METFORMIN AND SITAGLIPTIN IN HEALTHY HUMAN VOLUNTEERS' BLOOD PLASMA AND ITS BIOEQUIVALENCE STUDY UNDER FASTING CONDITION
Objective: Metformin hydrochloride and sitagliptin are the oral anti-hyperglycemic medications used to treat type 2 diabetes and are used in combination to treat patients. In this work, we have developed a bioanalytical method for simultaneous estimation of both the drugs form some formulation and subsequently the validation of the developed method metformin and sitagliptin in human plasma. Methods: The stability studies were done as per USFDA and EMA guidelines. The sample extraction approach presented here was a straightforward liquid extraction. The linearity range of metformin was 11.72 ng/ml to 3000 ng/ml, and sitagliptin was 4.68 ng/ml. to 1200 ng/ml. For metformin, the LOD was 1.0 ng/ml, and LLOQ was 11.72 ng/ml. and for sitagliptin, the LOD was 0.75 ng/ml, and LLOQ was 4.68 ng/ml. LC-ESI-MS/MS was used to develop and validate this method using the Phenomenex Kinetex C18 column. Milli-Q water containing 10 mmol Ammonium Acetate (pH =3.6) and Acetonitrile containing 0.1% Formic Acid (pH =2.4) as solvent systems for the estimation of Sitagliptin in a single dose. Metoprolol is used as an Internal Standard. Results: The total chromatographic run time was only 7.0 min, and the elute time of metformin and sitagliptin was 3.94 min and 3.97 min, respectively. Relative Bioavailability was found at 101.14% for Metformin and 96.96% for Sitagliptin. The overall results show that the Cmax, AUC0-t, and AUC0-∞ for metformin and sitagliptin were within the acceptable limit of 80%-125%. Conclusion: This bioanalytical method was successfully applied in the bioequivalence study. The study design was a randomized, open-label, two treatment, two-period, two sequences, single-dose, crossover bioequivalence study under fasting conditions.